Stakeholders in the Nigerian pharmaceutical industry share their views on how to make the National Vaccines Policy sustainable.
Nigeria is set to reap from the unintended consequence of the outbreak of COVID-19 pandemic disease, which chartered global socio-economic lives in the whole of 2020 and still ravaging on.
Woken by the devastation the pandemic wrecked on its national life and its exposure of the weaknesses in the country’s health sector, the federal government launched the Nigeria Vaccine Policy.
The policy was meant to encourage the manufacture of vaccines in Nigeria and enhance access to the use of vaccines for protection of its citizens from infectious diseases.
Speaking at the launch of the maiden edition of the NVP, the Minister of Health, Dr. Osagie Ehanire, declared that the policy would create a supportive environment for access and use of vaccines as well as setting the requirements and mandates for protection of citizens from internal and external harm.
Ehanire observed that there is need to resuscitate the local production of vaccines and intensify research and development along the same line.
The federal government, in furtherance of this objective, had a partnership with May and Baker Pharmaceutical that established the Biovaccine Nigeria Limited (BNL) to encourage local vaccine manufacturing.
In addition, the unveiling of the NVP would enable prospective domestic manufacturers to use appropriate technologies in modern vaccines production to boost local production of vaccines in Nigeria and make vaccines available to Nigerians and the entire West Africa.
He said: “A NVP will reflect new realities and trends, including the provisions enumerated in the Universal Health Coverage (UHC), Sustainable Development Goals (SDGs), National Health Act 2014, National Health Policy 2016 and PHC Under One Roof (PHCUOR). This will further ensure the development of strategies that will respond adequately to global health trends for emerging diseases and pandemic that impact on the Nigerian health system.
“Most importantly, the ongoing global efforts to develop COVID-19 vaccines further provide a strong justification for enacting a NVP in the interest of achieving vaccine security in Nigeria,”
He said the government has also taken a number of pragmatic steps towards boosting the local capacity for the manufacture of essential medicines “to ensure that the local pharmaceutical industry becomes a major actor in providing good quality essential medicines for our health care programs.
“It is my earnest hope that the launch of the third edition of the National Drug Policy will further increase the vibrancy of the pharmaceutical sector for the overall improvement of people’s health,” he said.
